Готові списки джерел за темами / Up-front chemotherapy

Добірка наукової літератури з теми "Up-front chemotherapy"

Автор: Grafiati

Опубліковано: 19 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Up-front chemotherapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Up-front chemotherapy":

&NA;. "'Up-front' chemotherapy successful in advanced germ cell tumours." Inpharma Weekly &NA;, no. 1290 (June 2001): 10. http://dx.doi.org/10.2165/00128413-200112900-00024.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhong, Lai-ping, Chen-ping Zhang, Guo-xin Ren, Wei Guo, William N. William, Jian Sun, Han-guang Zhu, et al. "Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma." Journal of Clinical Oncology 31, no. 6 (February 20, 2013): 744–51. http://dx.doi.org/10.1200/jco.2012.43.8820.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Purpose To evaluate induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy versus up-front surgery and postoperative radiotherapy in patients with locally advanced resectable oral squamous cell carcinoma (OSCC). Patients and Methods A prospective open-label phase III trial was conducted. Eligibility criteria included untreated stage III or IVA locally advanced resectable OSCC. Patients received two cycles of TPF induction chemotherapy (docetaxel 75 mg/m2 on day 1, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2 on days 1 to 5) followed by radical surgery and postoperative radiotherapy (54 to 66 Gy) versus up-front radical surgery and postoperative radiotherapy. The primary end point was overall survival (OS). Secondary end points included local control and safety. Results Of the 256 patients enrolled onto this trial, 222 completed the full treatment protocol. There were no unexpected toxicities, and induction chemotherapy did not increase perioperative morbidity. The clinical response rate to induction chemotherapy was 80.6%. After a median follow-up of 30 months, there was no significant difference in OS (hazard ratio [HR], 0.977; 95% CI, 0.634 to 1.507; P = .918) or disease-free survival (HR, 0.974; 95% CI, 0.654 to 1.45; P = .897) between patients treated with and without TPF induction. Patients in the induction chemotherapy arm with a clinical response or favorable pathologic response (≤ 10% viable tumor cells) had superior OS and locoregional and distant control. Conclusion Our study failed to demonstrate that TPF induction chemotherapy improves survival compared with up-front surgery in patients with resectable stage III or IVA OSCC.

Othman, Jad, Tasman Armytage, Kelly Wong, Christopher Arthur, Keith Fay, William Stevenson, Naomi MacKinlay, et al. "Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma." Bone Marrow Transplantation 55, no. 7 (January 20, 2020): 1460–63. http://dx.doi.org/10.1038/s41409-020-0789-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Maffezzini, Massimo, Alchiede Simonato, Marco Zanon, Marco Raber, and Giorgio Carmignani. "Up-Front Intravesical Chemotherapy for Low Stage, Low Grade Recurrent Bladder Cancer." Journal of Urology 155, no. 1 (January 1996): 91–93. http://dx.doi.org/10.1016/s0022-5347(01)66552-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hegenbart, Ute, Michael Rieger, Matthias Witzens, Manfred Hensel, and Anthony D. Ho. "Outcome of Patients with Primary Mediastinal Large B-Cell Non-Hodgkin’s Lymphomas: A Single Institution Analysis from 1996-2004." Blood 104, no. 11 (November 16, 2004): 3302. http://dx.doi.org/10.1182/blood.v104.11.3302.3302.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract Primary mediastinal large B-cell lymphoma represents a distinct subset of large B cell lymphoma, and it has been shown to occur preferentially in young females with a bulky mediastinal mass. Between 1996 and 2004, a total of 43 patients (pts) with primary mediastinal lymphoma were diagnosed and treated at our institution, 34 of them are evaluable for response and long-term follow-up. Twenty females and 14 males have been treated, the median age at diagnosis was 33 years (range: 18–56), 10 pts had stage I, 19 pts stage II and 5 pts stage III disease, respectively. Fifteen pts presented with B symptoms, LDH was increased in 68% of pts. First-line chemotherapy included CHOP (2 pts), R-CHOP (3 pts), CHOEP (8 pts), R-CHOEP (13 pts) or Mega-CHOEP (8 pts). 16 pts received Rituximab in combination with chemotherapy as front-line therapy. Complete response after first-line therapy has been observed in 71% and PR in 21% of pts. Later on, two pts in CR and 1 pt with PR relapsed after conventional chemotherapy. Radiotherapy was administered in 22 pts (65%) presenting with initial bulky disease. 19 pts have been autografted, 15 of them as part of up-front therapy. Indications for up-front autologous HCT were treatment within the Mega-CHOEP protocol (n=8), PR after first-line chemotherapy (n=3), IPI Score of 2 (n=2) and individual decision in 2 pts. Allogeneic HCT was performed as relapse therapy in 4 patients. Of the 15 pts who had up-front autologous HCT, 13 remained in CR. Overall, thirty pts were alive at the date of last contact with a median follow-up since diagnosis of 25 months (range 3–99). Three of 4 pts who had undergone allogeneic HCT in a advanced phase of disease died of transplant-related complications. In conclusion, in this patient group addition of Rituximab and/or dose-intensified first-line chemotherapy lead to a high rate of complete remissions as compared to historic controls. Whether up-front high-dose chemotherapy with autologous HCT or the administration of radiotherapy to the initial bulk improve PFS and OS remains an open question for this special lymphoma entity. The achievement of complete remission with primary treatment strategies seems to be essential to achieve long-term cure for this disease.

Göbel, U., D. T. Schneider, G. Calaminus, H. Jürgens, H. J. Spaar, W. Sternschulte, K. Waag, and D. Harms. "Multimodal Treatment of Malignant Sacrococcygeal Germ Cell Tumors: A Prospective Analysis of 66 Patients of the German Cooperative Protocols MAKEI 83/86 and 89." Journal of Clinical Oncology 19, no. 7 (April 1, 2001): 1943–50. http://dx.doi.org/10.1200/jco.2001.19.7.1943.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

PURPOSE: To evaluate a multimodal approach including surgery and cisplatinum chemotherapy for treatment of children with malignant sacrococcygeal germ cell tumors (GCT) and to compare adjuvant and neoadjuvant strategies in advanced tumors. PATIENTS AND METHODS: Between 1983 and 1995, 71 patients with malignant sacrococcygeal GCT were prospectively enrolled onto the German protocols for nontesticular GCT Maligne Keimzelltumoren 83/86 and 89. Five patients who received no chemotherapy (n = 2) or nonplatinum chemotherapy (n = 2) or who did not undergo tumor resection (n = 1) were excluded from this analysis. Among the 66 patients analyzed were 14 boys and 52 girls. The median age was 17.4 months (range, 7 months to 119 months). Median follow-up was 79 months (range, 4 months to 145 months). RESULTS: Fifty-two patients presented with locally advanced stage T2 tumors, and 30 patients had distant metastases at diagnosis. Patients received a median of eight cycles (range, four to nine cycles) of cisplatinum-based chemotherapy. Thirty-five patients underwent tumor resection at diagnosis and received adjuvant cisplatinum-based chemotherapy (group A). Thirty-one patients received up-front chemotherapy followed by delayed tumor resection (group B). Group B included more metastatic tumors than group A (group B, 19 of 31 patients; group A, 11 of 35 patients, P = .01). Preoperative chemotherapy facilitated complete tumor resections (group B, 20 of 31 patients; group A, five of 35 patients, P < .001) and avoided second-look surgery. Metastases at diagnosis and completeness of the first attempt of tumor resection were significant prognostic predictors; however, metastases were not predictive for patients treated with up-front chemotherapy. At 5 years follow-up, event-free survival was 0.76 ± 0.05 (50 of 66 patients), and overall survival was 0.81 ± 0.05 (54 of 66 patients). Four patients died as a result of therapy-related complications, and eight patients died of their tumors. Patients with locally advanced and metastatic tumors (T2b M1) fared better with neoadjuvant treatment [overall survival: 0.83 ± 0.09 (16 of 19 patients) versus 0.45 ± 0.15 (five of 11 patients), P = .01]. CONCLUSION: Even locally advanced and metastatic sacrococcygeal GCT can be successfully treated with up-front cisplatinum-based chemotherapy followed by delayed but complete tumor resection.

Steed, H., A. M. Oza, J. Murphy, S. Laframboise, G. Lockwood, D. De Petrillo, J. Sturgeon, and B. Rosen. "A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer." International Journal of Gynecologic Cancer 16, Suppl 1 (January 2006): 47–53. http://dx.doi.org/10.1136/ijgc-00009577-200602001-00008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The objective of this study is to compare progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients treated with neoadjuvant chemotherapy and surgery to primary surgery and postoperative chemotherapy. Retrospective analysis from 1998 to 2003 of 116 patients with ovarian cancer was performed. Fifty women diagnosed by positive cytology received three cycles of carboplatin and paclitaxel. Thirty-six patients subsequently underwent cytoreductive surgery and completed three further cycles postoperatively. The OS and PFS were compared in 66 women treated with primary surgery and postoperative chemotherapy. A statistically significant difference was observed for OS (P= 0.03, HR = 1.85, CI = 1.06–3.23) and PFS (P= 0.04, HR = 1.61, CI = 1.03–2.53) favoring the primary surgery group. Due to the small numbers, age, grade, stage, pleural effusions, and histologic cell type were controlled for separately in the bivariate analyses. Controlling for stage made the results weaker. A matched subgroup survival analysis was performed on patients who had surgery following neoadjuvant chemotherapy. After matching for stage and grade and controlling age and pleural effusions (N= 28 matched pairs), there was no statistical difference for OS (P= 0.95, HR = 1.04, CI = 0.33–3.30) or PFS (P= 0.79, HR = 1.11, CI = 0.98–1.04). It is concluded that primary surgery should be considered in all patients. Neoadjuvant chemotherapy may be an alternative in a subset of women with the intent to also perform interval debulking.

Coccolini, Federico. "Advanced ovarian cancer: Neoadjuvant chemotherapy plus surgery and HIPEC as up-front treatment." World Journal of Obstetrics and Gynecology 1, no. 4 (2012): 55. http://dx.doi.org/10.5317/wjog.v1.i4.55.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rakotonjanahary, Josué, Emilie De Carli, Matthieu Delion, Chantal Kalifa, Jacques Grill, François Doz, Pierre Leblond, Anne-Isabelle Bertozzi, and Xavier Rialland. "Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy." PLOS ONE 10, no. 6 (June 22, 2015): e0127676. http://dx.doi.org/10.1371/journal.pone.0127676.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bittoni, Alessandro, Mario Scartozzi, Mirco Pistelli, Eva Galizia, Michela Del Prete, Riccardo Giampieri, Luca Faloppi, Maristella Bianconi, Elena Maccaroni, and Stefano Cascinu. "Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first line matter?" Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 131. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.131.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

131 Background: The definition of the standard chemotherapy regimen for advanced gastric cancer is still a matter of debate. A recent meta-analysis suggested that the addition of a third drug to a doublet regimen should be considered the state-of-the-art strategy to improve overall survival. Aim of our analysis was to retrospectively assess whether an intensive, three-drugs, front line approach could be comparable to a sequential (two-drugs front line then second line) in terms of RR (response rate), PFS (progression free survival), and OS (overall survival) in advanced gastric cancer patients. Methods: Patients with metastatic gastric cancer who have received a first-line combination chemotherapy with a two or three-drugs regimen were included in our analysis. We divided our patients into two groups, A and B, based on the first line chemotherapy administered (group A=three drugs; group B= two drugs). Results: A total of 390 patients were eligible for our analysis. 211 patients (54%) received three chemotherapeutic agents (group A) and 179 patients (46%) received a two drugs regimen as first-line combination chemotherapy (group B). The 2 groups of patients resulted comparable for all known prognostic factors of clinical relevance. RR for group A and B was 46,5% and 28%, respectively (p=0,0007), median PFS was 7,12 months in group A and 3,96 months in group B (p<0,0001). No significantly difference resulted for the median OS of patients in the two groups (13 months for group A and 11,8 months for group B; p= 0,962). Conclusions: The addition of a third drug to a doublet chemotherapy regimen appeared more active in terms of response rate and PFS. However median OS resulted comparable. On this basis, a triplet regimen may represent an optimal choice, particularly when response and PFS are relevant treatment endpoints. Nevertheless the use of a sequential approach may also represent a reasonable strategy for patients unwilling or unable to undergo a more intensive treatment without compromising OS.

Більше джерел

Дисертації з теми "Up-front chemotherapy":

Rakotonjanahary, Ndrianjaka Josué. "Suivi à long terme des enfants traités pour gliome des voies optiques par chimiothérapie première BB-SFOP : survie à long terme - perte de la vision - outil d'interprétation des données IRMs." Thesis, Strasbourg, 2018. http://www.theses.fr/2018STRAJ116.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Les gliomes des voies optiques (GVO) sont des tumeurs bénignes pouvant être observées durant l’enfance. La prise en charge des GVO a évolué durant ces dernières décennies en évitant la radiothérapie et en donnant une place plus importante à la chimiothérapie. L’IRM est un des éléments fondamentaux dans la prise en charge. Cependant, les mesures tumorales sont soumises à des importantes variabilités inter et/ou intra-observateur. Pour mieux comprendre le devenir à long terme des enfants traités par chimiothérapie initiale, le devenir des enfants traités en France pour GVO par chimiothérapie initiale BB-SFOP a été évalué. Un outil standardisé permettant des interprétations fiables et reproductibles des IRMs a été créé et validé. La survie globale de ces patients montre un plus mauvais pronostic à long terme. Certains facteurs cliniques et radiologiques sont également associés à une perte de la vision observée à long terme. Ces découvertes pourraient justifier la mise en place d’une prise en charge adaptée en fonction du niveau de risque
Optic Pathway Gliomas (OPG) are benign tumors that typically develop during early childhood. The management of patients varied throughout the last decades and was characterized by an emphasis on avoiding the use of radiotherapy. The role of chemotherapy in the management of OPG has increased. MRI is one of the fundamental elements of the management of these children. However, the tumor measurements are subject to inter and/or intraobserver variations. In an attempt to better understand the long-term outcomes of children treated with initial chemotherapy, long-term outcomes of OPG treated in France with up-front BB-SFOP chemotherapy were evaluated. A standardized and reproducible imaging classification for MRI that can be used as a reliable monitoring tool for patients with OPG was created and validated. The long-term outcomes of these patients showed a poorer prognosis for overall survival. Some clinical and radiological factors were associated with long-term vision loss. These findings could justify a risk-based approach to this tumor

Частини книг з теми "Up-front chemotherapy":

Goldstein, Inge F., and Martin Goldstein. "Breast Cancer, Part 1: The Rise Of Activism and The Pesticide Hypothesis." In How Much Risk? Oxford University Press, 2002. http://dx.doi.org/10.1093/oso/9780195139945.003.0010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The New York Post, a New York City daily, ran a sensational headline on the front page of its April 12, 2000, issue: “Breast Cancer Hot Spots”. The news story reported that statistics and maps of breast cancer rates just released by New York State health authorities showed unusually high rates of breast cancer on the Upper East Side of Manhattan, as well as on Long Island and several other areas in New York City and upstate. These high rates were described by the state authorities as “not likely due to chance.” The residents of the Upper East Side, one of the most affluent areas of the city, were understandably alarmed. One woman interviewed was considering whether to move elsewhere, but had not yet decided. A second demanded that the two major party candidates for the U.S. Senate state their positions on the high rate. A third noted that there were no obvious sources of pollution in the neighborhood, no pesticide spraying or toxic waste dumps, that could explain why the breast cancer rate was high. Many people believe that breast cancer is caused by toxic agents in the environment. Victims of breast cancer we have met at sessions of support groups have described vividly the pains and discomfort of chemotherapy, radiation, and radical surgery; the nagging anxiety about a possible recurrence, the sense of disfigurement, of mutilation; the ignorance and insensitivity of many of the so-far healthy; the strengthening or weakening of bonds to those close to them: husbands, sons, daughters, parents, who either grow in understanding and compassion or fall short. But there is one common thread that runs through their stories: each of them feels there must be a reason why she, at this particular point in her life, should have gotten this terrible disease. Why me? Lucia D., in her late thirties, remembers that as a child of eight or nine growing up in Panama she and other children used to run after the truck that periodically sprayed DDT in their neighborhood and dance around in the spray. She is convinced that this childhood exposure is the reason she has breast cancer at such an early age.